Trial Profile
A Phase I, Multi-center, Randomized Open Label Study to Assess the Systemic Exposure and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms ASCEND-8
- Sponsors Novartis; Novartis Pharmaceuticals
- 31 Jan 2021 Results of final analysis presented at the 2020 World Conference on Lung Cancer
- 21 Sep 2020 Results (data cut-off : March 6, 2020; n=198) from Asian patients presented at the 45th European Society for Medical Oncology Congress
- 24 Mar 2020 Status changed from active, no longer recruiting to completed.